Supply@ME replaces Negma deal with new loan facility

Supply@ME replaces Negma deal with new loan facility

SYME has agreed with ARC an initial loan tranche of £5mln, with a further £2mln available within 60 days

Supply@ME

Supply@ME Capital PLC agreed terms on a short-term loan facility with ARC Group, an investment bank that works with family offices and institutions to arrange funding.

The new facility will replace a convertible loan subscription agreement signed with Negma Group, the stock monetisation platform said.

Negma will receive 840mln of new shares under the agreement while the residual portion of £2.1mln convertible notes will be repaid in cash funded by the new facility.

As part of the deal, Negma has agreed not to short Supply@ME shares while the deal unwinds and not to sell more than 25% of daily value traded on any given day,

Supply@ME agreed with ARC an initial loan tranche of £5mln, with a further £2mln available within 60 days.

The facility is for 12 months at an interest rate of 10% with warrants attached worth up to 20% of the £7mln loan.

The short-term loan facility will be linked to a Convertible Loan Note facility with Supply@ME also working with ARC to explore a dual listing on NASDAQ, the statement said.

Alessandro Zamboni, Supply@ME Capital’s chief executive, added: “This is a key development for Supply@ME providing us with further flexibility to execute our plans and accelerate our expansion in key markets.

“ARC was impressed with our recent developments, confirmed by the recent trading update and the related revenue guidance.

“I am very pleased to strengthen our relationship with ARC at this important stage in our company’s growth and I look forward to working with them closely as we further our efforts towards a dual listing.”

Continue reading

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited. The transaction marks […]
Rising Together | ARC Dragon Boat Team Takes to the Water
Bio Green Med Solution, Inc. Announces Business Combination Agreement to Acquire Future NRG Sdn. Bhd.
Inside ARC Group | University of Nottingham Ningbo China

Please complete this form to download the case study

This field is for validation purposes and should be left unchanged.
*Required before submission